MedTrace Logo

Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

NCT01758471 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2013-01-01

No results posted yet for this study

Summary

This study is aimed to investigate the effect of acarbose on intestinal microbiome and incretins, therefore to explore the new pathways or new targets to treat type 2 diabetes.

Conditions

Interventions

DRUG

Glipizide

glipizide 5mg per pill 5mg tid p.o. for 3 month

DRUG

Acarbose

Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Guang Ning, M.D. Ph.D. · Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01758471 on ClinicalTrials.gov